BioReliance Expands Genetic Tox Services

BioReliance Corp. has expanded its Rockville facilities and staff to accommodate the growing demand for its genetic toxicology testing services. BioReliance provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries.
   
The expanded gene tox facilities features new labs and additional scientific staff for these services. In March 2008, the company restructured its toxicology and LADS services, forming a new business unit — Toxicology and LADS — headed by Darryl L. Goss, vice president.
   
Government regulations require gene tox testing to identify the potential of drugs, chemicals and other products to damage DNA. With pharmaceuticals, these tests are used throughout the drug development process, including discovery, lead optimization, preclinical safety testing and to further investigate mechanism of action to help characterize human risk.
   
“Expanding the facility is in response to the growing needs of the industry. Our dedicated staff works closely with regulatory agencies and customers to ensure faster and safer drug development. The additional capacity will allow us to serve our client’s screening and regulatory required testing needs faster and more efficiently with the highest degree of precision,” said Mr. Goss.